Navigation Links
IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
Date:4/30/2010

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- IRIDEX Corporation, (Nasdaq: IRIX) today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

"The time and effort we invested to perfect our core system platform and obtain regulatory approval for a family of laser products has made it possible to introduce the IQ 532 green laser within one year of shipping the IQ 577 yellow laser," commented Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX.  "Continuing with this platform approach, we look forward to the timely introduction of additional systems currently under development."

As with the IQ 577, the IQ 532 features dual port laser output as well as a graphic, touchscreen interface.  Dual port connectivity provides the physician with the added convenience and efficiency by permitting the exchange of multiple delivery devices with one-touch speed and simplicity.  Setup and use of the IQ 532 system for surgery is quick, easy and intuitive, thanks to its superior ergonomics and user interface.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to IRIDEX's statements relating to our common platform approach, the benefits of such approach and future product development. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010, which was filed with the Securities and Exchange Commission on March 31, 2010. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
2. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
3. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
4. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
6. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
7. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli Lilly ... William Sansum Diabetes Center have established a research collaboration ... diabetes through enhanced research, education and care. ... bears a disproportionate weight on Latino families in ... Kerr , M.D., FRCPE, director of Innovation and Research ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... latest Pharmaceutical and Healthcare disease pipeline guide Primary ... overview of the Primary Hyperoxaluria (Genito Urinary System ... is a rare condition characterized by recurrent kidney ... of a substance called oxalate. Symptoms include blood ...
(Date:3/23/2017)... Texas , March 23, 2017  Digital ... www.digitalpharmacist.com ), a rapidly growing digital health ... a mobile app that allows patients to manage ... multi-store locations such as Denver Health Pharmacy, USave ... The acquisition helps Digital Pharmacist accelerate its product ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “End Time ... the salient events will interrelate. “End Time GPS” is the creation of published ... explosives expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
Breaking Medicine News(10 mins):